What Is PMS?

Premenstrual Syndrome (PMS) is a set of physical, emotional, and behavioral symptoms that occur cyclically during the luteal phase of the menstrual cycle (7 to 14 days before menstruation) and that resolve with the onset of menstrual flow.

Up to 80% of women of reproductive age experience some premenstrual symptom, but only 20-40% meet criteria for clinically significant PMS. The most severe form, Premenstrual Dysphoric Disorder (PMDD), affects 3-8% of women and is recognized as a distinct psychiatric entity in the DSM-5.

PMS is not an invented or exaggerated condition — it has a proven neurobiologic basis, involving the interaction between ovarian hormones and brain neurotransmitters. The impact on quality of life, relationships, and productivity can be substantial.

1

Neurobiologic Basis

PMS results from abnormal brain sensitivity to normal estrogen and progesterone fluctuations, affecting the serotonergic system.

2

Cyclical Pattern

Symptoms emerge in the luteal phase (post-ovulation) and resolve with menstruation. This cyclical pattern is an essential diagnostic criterion.

3

PMDD: Severe Form

Premenstrual dysphoric disorder affects 3-8% of women with severe emotional symptoms that significantly compromise functioning.

Pathophysiology

PMS pathophysiology does not involve abnormal ovarian hormone levels — estrogen and progesterone are normal. The central mechanism is an abnormal brain sensitivity to the physiological fluctuations of these hormones, particularly progesterone and its active metabolite, allopregnanolone.

Allopregnanolone is a neurosteroid that modulates GABA-A receptors in the brain, the main inhibitory system of the central nervous system. In women with PMS, the brain response to allopregnanolone is altered — instead of an anxiolytic effect, there may be a paradoxical anxiogenic effect, contributing to irritability, anxiety, and dysphoria.

Interaction between ovarian hormones, neurosteroids, and the serotonergic system in the pathophysiology of PMS/PMDD
Interaction between ovarian hormones, neurosteroids, and the serotonergic system in the pathophysiology of PMS/PMDD

The serotonergic system plays a central role. Fluctuations in estrogen and progesterone modulate the synthesis, release, and reuptake of serotonin. In the luteal phase, women with PMS show reduced serotonergic activity, which explains the efficacy of selective serotonin reuptake inhibitors (SSRIs) even in intermittent use.

Contributing factors include calcium and magnesium deficiency, alterations in the renin-angiotensin-aldosterone axis (water retention), and altered GABA sensitivity. Genetic predisposition is evident — twin studies demonstrate heritability of 30-50%.

Symptoms

More than 150 symptoms have been linked to PMS. Symptoms can be divided into emotional/behavioral and physical. The combination and intensity vary among women and may vary between cycles in the same woman.

Emotional and Behavioral Symptoms

  • Irritability and anger

    Most frequent symptom, affecting up to 80% of women with PMS. A mismatch between stimulus and emotional response.

  • Anxiety and tension

    Apprehension, nervousness, and muscle tension, frequently accompanied by insomnia.

  • Depressed mood

    Sadness, tearfulness, and hopelessness. In PMDD, may reach clinically significant intensity.

  • Difficulty concentrating

    Reduced attention, "mental fog", and lower cognitive productivity during the luteal phase.

  • Food cravings

    Intense cravings for carbohydrates and sweets, possibly tied to the brain's attempt to raise serotonin.

  • Social isolation

    Tendency to avoid social interactions and feeling overwhelmed by daily demands.

Physical Symptoms

  • Mastalgia (breast pain)

    Bilateral breast engorgement and tenderness, tied to water retention and progesterone effects.

  • Abdominal distension and edema

    Abdominal bloating and edema of extremities from sodium and water retention mediated by aldosterone.

  • Headache

    May be tension-type or migrainous, tied to hormonal fluctuations, especially estrogen drops.

  • Fatigue

    Fatigue disproportionate to effort, frequently tied to luteal-phase sleep disturbances.

  • Muscle and joint pain

    Diffuse myalgia and arthralgia, possibly mediated by prostaglandins and mild inflammatory changes.

Diagnosis

PMS diagnosis is clinical and requires prospective documentation of the cyclical symptom pattern. No laboratory test confirms the diagnosis. Hormonal measurements are normal and not indicated.

The essential criterion is the temporal restriction: symptoms must be present in the luteal phase, absent in the follicular phase (days 4-12 of the cycle), and cause functional impairment. At least 5 symptom-free days after menstruation are required to differentiate PMS from chronic disorders.

ACOG Diagnostic Criteria for PMS

  1. At least 1 clinically significant emotional or physical symptom in the 5 days before menstruation
  2. Symptoms present in at least 3 consecutive cycles (prospective documentation)
  3. Symptom relief within 4 days after menstruation begins
  4. At least 5 symptom-free days in the follicular phase
  5. Identifiable functional impairment (social, professional, relational)
  6. Not attributable to another psychiatric or medical condition
80%
of women have some premenstrual symptom
20-40%
meet criteria for clinical PMS
3-8%
have PMDD (severe form)
2 cycles
minimum prospective documentation for diagnosis

Differential Diagnosis

Premenstrual Dysphoric Disorder

Read more
  • Severe psychiatric symptoms (depressed mood, severe anxiety)
  • Significant functional dysfunction at work and in relationships
  • Cycles documented with PRISM or DRSP
Warning signs
  • Suicidal ideation
Diagnostic testsProspective symptom diary for 2 cycles (DRSP)Psychiatric evaluation

Adjunctive to pharmacologic treatment (SSRIs) for PMDD; contributes to anxiety reduction and mood regulation

Depression

Read more
  • Depressive symptoms not exclusively premenstrual
  • Also present in the follicular phase
  • Elevated scores on depression scales (PHQ-9)
Warning signs
  • Suicidal ideation
  • Severe dysfunction
Diagnostic testsSymptom diaryPHQ-9Psychiatric evaluation

Moderate evidence for reducing depressive symptoms; adjunctive to psychotherapy and pharmacotherapy

Generalized Anxiety

Read more
  • Persistent anxiety not related to the cycle
  • Generalized and non-cyclical worry
  • Physical symptoms of tension outside the luteal phase
Diagnostic testsGAD-7Symptom diary for 2 cycles

Preliminary evidence for reducing anxiety symptoms; the proposed mechanisms (HPA axis modulation, endogenous opioids) are still under investigation

Hypothyroidism

Read more
  • Fatigue, weight gain, constipation
  • Cold intolerance
  • Symptoms not exclusively premenstrual
Diagnostic testsTSH and free T4

Adjunctive to hormonal treatment; does not replace levothyroxine

Endometriosis

Read more
  • Progressive dysmenorrhea
  • Chronic pelvic pain not only premenstrual
  • Deep dyspareunia
Warning signs
  • Associated infertility
Diagnostic testsTransvaginal ultrasoundPelvic MRI

Modulation of central sensitization and chronic pain as part of multimodal management

Premenstrual Dysphoric Disorder (PMDD)

PMDD is the severe form of PMS, recognized as a diagnostic entity in the DSM-5. Psychiatric symptoms are predominant and severe — marked depressed mood, intense dysphoria, elevated anxiety — and cause significant functional dysfunction at work, in relationships, and in daily activities. It affects 3-8% of women of reproductive age.

Differential diagnosis is fundamental because PMDD requires specific pharmacologic treatment (SSRIs, particularly paroxetine and sertraline during the luteal phase). Acupuncture may be incorporated as an adjunct, contributing to mood regulation and anxiety reduction, but does not replace pharmacotherapy in severe PMDD.

Depression and Generalized Anxiety

Differentiating PMS from primary mood disorders rests on symptom timing. In PMS and PMDD, symptoms are strictly cyclical — they emerge in the luteal phase and disappear once menstruation begins. In depression and generalized anxiety, symptoms are present across all phases of the cycle and may intensify premenstrually.

The reference diagnostic instrument is a prospective symptom diary (DRSP or PRISM) over at least 2 cycles. Absence of a symptom-free period in the follicular phase rules out PMS/PMDD and suggests an underlying mood disorder that requires specific psychiatric evaluation.

Hypothyroidism

Hypothyroidism may cause symptoms that resemble PMS — fatigue, weight gain, irritability, sleep disturbances, and depression. Clinical differentiation rests on the absence of the typical cyclical pattern: in hypothyroidism, these symptoms persist throughout the entire menstrual cycle, not exclusively premenstrually.

TSH measurement should be part of the basic workup for any woman with premenstrual symptoms, especially when fatigue and weight gain are prominent. Adequate treatment of hypothyroidism frequently resolves symptoms without specific PMS intervention.

Treatment

PMS treatment follows a stepwise approach, starting with lifestyle modifications and progressing to pharmacotherapy according to severity. For PMDD, SSRIs are the first-line treatment with proven efficacy.

Lifestyle Modifications

Regular aerobic exercise (30-60 min, 3-5x/week), reduced caffeine, alcohol, and sodium, and a diet rich in complex carbohydrates. Calcium (1,200 mg/day) is the supplement with the best evidence.

Supplementation

Calcium (1,200 mg/day — one randomized clinical trial showed symptoms reduced by about half; moderate evidence), magnesium (200-360 mg/day), vitamin B6 (50-100 mg/day), vitex agnus-castus (20-40 mg/day). Moderate evidence for all.

SSRIs (First Line for PMDD)

Fluoxetine (20 mg), sertraline (50-150 mg), escitalopram (10-20 mg). May be used continuously or only in the luteal phase (intermittent use). Effective in 60-70% of PMDD cases.

Hormonal Contraceptives

Drospirenone + ethinylestradiol on a 24/4 regimen (approved for PMDD). Suppress ovulation and hormonal fluctuations. Alternative when SSRIs are not tolerated or desired.

The essentials so far
  1. PMS treatment follows a stepwise approach, starting with lifestyle modifications and progressing to pharmacotherapy according to severity.
  2. For PMDD, SSRIs are the first-line treatment with proven efficacy.
  3. Calcium (1,200 mg/day) is the supplement with the best evidence.
Continue: Acupuncture as Treatment

Acupuncture as Treatment

Acupuncture is investigated as a complementary therapy for PMS, with preliminary studies suggesting possible benefit for physical and emotional symptoms. Proposed mechanisms — still under investigation — include possible modulation of neurotransmitter systems (serotonin, GABA) and autonomic tone, alongside endogenous-opioid effects. There is no firm evidence that acupuncture alters hormone levels; it does not replace SSRIs or contraceptives when indicated.

Systematic reviews and meta-analyses suggest reduction of overall PMS symptoms compared with control, with variable effect magnitude across studies and heterogeneous methodological quality. The reported benefit covers both physical symptoms (mastalgia, distension) and emotional symptoms (irritability, anxiety), but the robustness of this evidence is still limited.

Acupuncture may be especially valuable for women who prefer to avoid medication, have contraindications to SSRIs or contraceptives, or wish to complement pharmacologic treatment. In trials, the number of sessions ranged from 7 to 28, usually concentrated in the luteal phase, over 2 to 3 cycles or more; there is no standardized protocol.

Prognosis

PMS is a chronic condition that persists as long as ovulatory menstrual cycles continue. Symptoms typically cease with menopause, pregnancy, and during use of medications that suppress ovulation.

With adequate treatment, most women achieve significant improvement in quality of life. SSRIs are effective in 60-70% of PMDD cases, and combining approaches (lifestyle, supplements and, when indicated, pharmacotherapy) tends to extend the benefit.

It is important to recognize that PMS may be a risk factor for depression in perimenopause and the postpartum period. Women with PMDD should be monitored across hormonal transitions for early detection of mood disorders.

60-70%
respond to SSRIs in PMDD
48%
symptom reduction with calcium 1,200 mg/day in one trial (placebo: 30%)
Most
improve with adequate treatment
Menopause
natural resolution of symptoms

Myths and Facts

Myth vs. Fact

Myth

PMS is silliness or exaggeration

Fact

PMS and PMDD are medical conditions with a proven neurobiologic basis. PMDD is classified as a psychiatric disorder in the DSM-5. Symptoms result from the interaction between ovarian hormones and brain neurotransmitters.

Myth

All women have PMS the same way

Fact

Intensity varies enormously. While mild symptoms are common, only 20-40% meet clinical criteria. Severity is determined by individual brain sensitivity to hormonal fluctuations.

Myth

Chocolate cures PMS

Fact

Sweet cravings may reflect the brain's attempt to raise serotonin via tryptophan. Although they bring momentary relief, they don't treat the cause. Calcium and exercise have much more robust evidence.

Myth

PMS hormones are "out of control"

Fact

Hormone levels in PMS are normal. The problem is abnormal brain sensitivity to physiologic fluctuations, mediated by altered GABA and serotonin receptors.

When to Seek Help

If premenstrual symptoms interfere with work, relationships, or quality of life, seek medical evaluation. Effective treatments are available and can transform the menstrual experience.

Frequently Asked Questions

Related Reading

Deepen your knowledge with related articles